C12N 2810/50
Vectors comprising as targeting moiety peptide derived from defined protein
C12N2810/50 (Vectors comprising as targeting moiety peptide derived from defined protein) appears on 708 US grants and 1,116 published applications in this corpus.
Search patents in C12N- Granted patents
- 708
- Published applications
- 1,116
- Assignees
- 500
- Inventors
- 1,799
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 4 | 0 |
| 1998 | 10 | 0 |
| 1999 | 18 | 0 |
| 2000 | 16 | 0 |
| 2001 | 22 | 8 |
| 2002 | 23 | 44 |
| 2003 | 24 | 63 |
| 2004 | 20 | 54 |
| 2005 | 15 | 51 |
| 2006 | 21 | 56 |
| 2007 | 23 | 40 |
| 2008 | 20 | 43 |
| 2009 | 20 | 42 |
| 2010 | 21 | 59 |
| 2011 | 13 | 34 |
| 2012 | 24 | 44 |
| 2013 | 21 | 36 |
| 2014 | 43 | 49 |
| 2015 | 37 | 65 |
| 2016 | 29 | 56 |
| 2017 | 45 | 46 |
| 2018 | 37 | 63 |
| 2019 | 41 | 48 |
| 2020 | 34 | 41 |
| 2021 | 22 | 46 |
| 2022 | 20 | 32 |
| 2023 | 26 | 20 |
| 2024 | 22 | 36 |
| 2025 | 19 | 22 |
| 2026 | 10 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- S. pyogenes CAS9 mutant genes and polypeptides encoded by same1 Sep 2026US 12,723,264 B2Integrated Dna Technologies, Inc.
- Methods and compositions for enhanced protein production in Bacillus cells18 Aug 2026US 12,709,755 B2Danisco US Inc.
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems16 Jun 2026US 12,653,905 B2Nanora Pharma Inc.
- RNA-guided human genome engineering9 Jun 2026US 12,649,928 B2President and Fellows of Harvard College
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Methods and Systems for Rapid Engineering of Resting Cells13 Aug 2026US 2026/0234558 A1Cellfe, Inc.
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Compositions and methods for integration of viral vectors30 Jul 2026US 2026/0218237 A1Poseida Therapeutics, Inc.
- RNA-Guided Human Genome Engineering23 Jul 2026US 2026/0209792 A1President and Fellows of Harvard College
- Modified aav particles16 Jul 2026US 2026/0200989 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Engineering of systems, methods and optimized guide compositions for sequence manipulation480US 8,906,616 B2Massachusetts Institute of Technology · 2014
- RNA-guided human genome engineering263US 9,023,649 B2President and Fellows of Harvard College · 2015
- TAL effector-mediated DNA modification216US 8,440,431 B2Iowa State University Research Foundation, Inc. · 2013
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Tal effector-mediated DNA modification187US 8,440,432 B2Iowa State University Research Foundation, Inc. · 2013